我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
6
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
1
16.7%
招募中
5
83.3%
暂无批准数据
- Avalyn Pharma will present the AURA-IPF Phase 2 clinical trial design for AP02, an inhaled formulation of nintedanib, at the European Respiratory Society International Congress 2025. - Phase 1 studies demonstrated that AP02 achieved improved drug concentrations in the lungs and reduced systemic exposure compared to oral nintedanib, the current standard of care. - The inhaled delivery approach may provide enhanced therapeutic benefit with fewer side effects, potentially enabling long-term treatment for idiopathic pulmonary fibrosis patients. - Avalyn's pipeline includes AP01, an inhaled pirfenidone formulation currently in Phase 2b trials, which has shown improved efficacy and safety in over 150 patients with pulmonary fibrosis.
